Lonza to Expand Development Services for Mammalian Products in Singapore
- As part of continued investment in Asia, Lonza is expanding mammalian development services at its Singapore facility
- This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
- The expansion aims to double the existing laboratory footprint and create 70 new positions in the current development services team
Basel, Switzerland, 07 October 2021 – Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, today announced it will invest to expand mammalian development services in Singapore. The expansion will establish additional capacity for cell culture, purification, and analytical services for mammalian biologics.
The increased service capabilities complement the existing offering, consisting of cell line construction services, process development and process characterization services at the mammalian and cell therapy manufacturing site in Singapore.
This investment will expand the current laboratory capabilities by establishing a new 1,800m2 laboratory at Singapore Science Park, increasing the headcount of the mammalian development services team in Singapore to 125 employees. The new laboratory began operations in September. As part of the investment, the existing laboratories at Lonza’s Tuas, Singapore site will be upgraded by the end of 2021.
Jeetendra Vaghjiani, Senior Director of Clinical Development for Mammalian Biologics, Lonza, commented: “The growth of our global manufacturing network brought a need to increase services supporting these assets. The investment to expand our mammalian manufacturing services in Singapore will ensure that our team continues to deliver timely support to our customers, in particular for process development and characterization studies necessary for advancing therapies towards regulatory approvals and commercialization.”
As part of the expansion, Lonza will invest in the latest technology for mammalian process and analytical development through the addition of systems for cell line development, the latest in perfusion and process analytical technology for process development, as well as providing the capability to perform extensive characterization of biopharmaceuticals using mass spectrometry for the first time in Singapore. The investment will also provide opportunities to expand the service offering and strengthen the position for the anticipated market growth in complex protein formats.
The addition of new technology, alongside the increase in capacity and headcount of Lonza’s development services team in Singapore, will provide a comprehensive offering for small- and large-scale GMP mammalian manufacturing services and cell therapy capabilities.
To learn more about our mammalian manufacturing in Singapore, visit: https://pharma.lonza.com/about/locations/tuas-singapore.